Strata Oncology
Ann Arbor, US · Founded 2015 · Delaware corporation · 5 known investors
Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies. Its algorithms combine measures such as tumor mutation burden and gene expression to help match patients to the most suitable therapy.
AI & Machine LearningBiotechDigital HealthMedical Devices
Founders & leadership
Strata Oncology was founded in 2015 by Daniel Rhodes.
DR
Daniel RhodesFounder
MM
Matthew MartinExecutive
JW
Jeffrey WilliamsExecutive
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$29.2M disclosed across 4 rounds · 2016–2024
▶$6.1MraisedNov 2024 · 14 investors · OtherRule 506(b)
▶$6.1MraisedNov 2024 · 14 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Matthew MartinExecutive Officer
- Daniel RhodesExecutive Officer, Director
- Keith FlahertyDirector
- Christopher O'DonnellDirector
- Jeffrey WilliamsExecutive Officer, Director
- David RubinDirector
- James PavlikDirector
- Jan GarfinkleDirector
- Offering amount
- $10M
- Amount sold
- $6.1M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedNov 2020 · 9 investors · OtherRule 506(b)
▶$5MraisedNov 2020 · 9 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- William BurkothDirector
- Prem TumkositDirector
- Jeffrey WilliamsExecutive Officer, Director
- Jan GarfinkleDirector
- Daniel RhodesExecutive Officer, Director
- Matthew MartinExecutive Officer
- Nicole WalkerDirector
- Keith FlahertyDirector
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.8MraisedMay 2018 · 7 investors · OtherRule 506(b)
▶$11.8MraisedMay 2018 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Prem TumkositDirector
- Matthew MartinExecutive Officer
- Keith FlahertyDirector
- William BurkothDirector
- Nicole WalkerDirector
- Jeffrey WilliamsDirector
- Jan GarfinkleDirector
- Daniel RhodesExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $11.8M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$6.3MraisedMar 2016 · 6 investors · OtherRule 506(b)
▶$6.3MraisedMar 2016 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Matthew MartinExecutive Officer
- Jeffrey WilliamsDirector
- Daniel RhodesExecutive Officer, Director
- Offering amount
- $12.3M
- Amount sold
- $6.3M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapLabcorp30 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
Genomeweb29 shared keywordsGenomeWeb's Research Funding section publishes news coverage of research grants and government funding trends in genetics, genomics, and molecular diagnostics. It is an industry news publication serving researchers and organizations in the life sciences.
Exact Sciences24 shared keywordsExact Sciences develops diagnostic tests for cancer, including tests that assess hereditary risk, screen for the presence of cancer, and analyze the genomic alterations of a diagnosed cancer to inform treatment decisions. Its products serve patients and clinicians in oncology diagnostics.
Companies competing with Strata Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Strata Oncology do?
- Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies. Its algorithms combine measures such as tumor mutation burden and gene expression to help match patients to the most suitable therapy.
- Who founded Strata Oncology?
- Strata Oncology was founded by Daniel Rhodes in 2015.
- Who are Strata Oncology's investors?
- Strata Oncology's investors include Arboretum Ventures, Pfizer Venture Investments, Deerfield Management Company, Merck Global Health Innovation Fund, Pfizer Ventures.
- How much funding has Strata Oncology raised?
- Strata Oncology has disclosed $29.2M raised across 4 rounds.
- Where is Strata Oncology headquartered?
- Strata Oncology is headquartered in Ann Arbor, US.